GET DAILY SIGNALSMilestone Pharmaceuticals (MIST) +7% Over 30 Days: Following the CARDAMYST Launch Progress
Key Takeaways
- MIST shares have risen roughly 7% over the trailing 30 days, from a close near $0.71 to about $0.76, though the stock remains well below levels reached earlier in 2026.
- Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company focused on cardiovascular medicines, led by its FDA-approved CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT).
- The mid-February 2026 commercial launch of CARDAMYST is the central investment narrative, with prescriptions, unique prescribers, and payer coverage all expanding through the first half of the year.
- A pivotal Phase 3 program (ReVeRA-301) evaluating etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) targets a substantially larger patient population and is now enrolling participants.
- The company reported about $170.6 million in cash and investments as of mid-2026, with an expected runway into the second half of 2027.
- For additional detail on valuation and expectations, explore Milestone's Price Targets, Earnings, and Forecast pages.
- For automated, data-driven trading ideas across the market, explore Trending AI Robots.
Current Market Snapshot
MIST has traded in a relatively narrow range in recent weeks, with the stock moving from a close near $0.71 in early October to about $0.76, a gain of roughly 7% over the trailing 30 days. That modest recovery follows a broader pullback from the higher levels the shares reached earlier in 2026, when investor enthusiasm around the CARDAMYST launch pushed the stock considerably above its current price.
Sentiment remains tied to the early commercial traction of CARDAMYST and to clinical milestones in the AFib-RVR program. As a small-cap, pre-profitability biotech in an active launch phase, MIST continues to attract attention primarily from specialists and growth-oriented investors tracking prescription trends, payer coverage decisions, and regulatory timelines rather than near-term earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Milestone Pharmaceuticals (MIST) Business Overview and Competitive Position
Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, is a calcium channel blocker approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. The product is designed as a self-administered, rapid-response therapy that patients can use outside a healthcare setting, addressing an unmet need in a market that had seen little therapeutic innovation for decades.
Beyond its approved indication, Milestone is developing etripamil in a Phase 3 registrational trial (ReVeRA-301) for AFib-RVR and in earlier-stage work for pediatric PSVT. The company's competitive positioning rests on its first-mover status in self-administered acute tachycardia care, an established calcium channel blocker mechanism, and a broad clinical dataset supporting CARDAMYST. Investors follow MIST closely because the trajectory of the CARDAMYST launch and the expansion into AFib-RVR define both near-term revenue potential and the long-term value of the franchise.
Recent Developments Driving MIST
The dominant driver of MIST's narrative over recent months has been the execution of the CARDAMYST launch. Management reported more than 1,500 total prescriptions filled for over 1,300 patients through the first half of 2026, with more than 800 unique prescribers. Commercial coverage expanded meaningfully after the second quarter, crossing approximately 50% of commercially insured lives following formulary wins with UnitedHealthcare and other plans using Express Scripts or Optum Rx.
On the clinical and regulatory front, Milestone announced in early September 2026 that China's National Medical Products Administration had approved etripamil nasal spray for PSVT, marking the first approval outside the United States and triggering a $2.0 million milestone payment under the company's partnership with Everest Medicines. The company has also begun enrolling the ReVeRA-301 Phase 3 trial for AFib-RVR, with the first Canadian and European participants announced in late September and early October 2026, and presented new data at the AHA Scientific Sessions 2026 showing CARDAMYST converted recurrent PSVT in patients with prior catheter ablation.
Analyst activity has remained generally constructive. Raymond James lowered its price target to $5 from $6 in October 2026 while maintaining a Strong Buy rating, citing improving payer coverage and encouraging prescription growth. Piper Sandler has reiterated a Buy rating with a higher target. These developments have supported sentiment even as the company continues to report widening net losses associated with launch-related spending.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important near-term catalysts include the company's third-quarter 2026 financial results, scheduled for mid-November 2026, which will provide updated prescription, prescriber, coverage, and revenue figures for the CARDAMYST launch. Continued expansion of commercial and Medicare coverage, as well as average selling price and gross-to-net trends, will be closely watched indicators of whether early adoption is translating into meaningful revenue.
On the pipeline side, progress in the ReVeRA-301 Phase 3 trial for AFib-RVR and the expected decision from the European Medicines Agency on etripamil for PSVT in the first half of 2027 are key value-driving milestones. Investors should also monitor cash burn against the company's projected runway into the second half of 2027, competitive dynamics in the cardiology space, and any additional analyst ratings or price target revisions. These factors, rather than near-term earnings, are likely to shape sentiment around MIST through 2026 and into 2027.
Exploring AI-Driven Trading Strategies
In my own research process, I sometimes review Tickeron’s Trending AI Robots to see how automated strategies are performing across the broader market. The section highlights top bots with different timeframes and approaches, which can provide a data-driven perspective that complements fundamental analysis of names like MIST.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIST's Indicator enters downward trend
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 189 of the 212 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MIST's RSI Oscillator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 57 cases where MIST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MIST as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MIST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement